World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
58
Citations
17729
World Ranking
3469
National Ranking
299

Overview

Mark T. Esser is affiliated with AstraZeneca in the United Kingdom. Their research primarily focuses on the field of Medicine, with a strong emphasis on Infectious Diseases, Epidemiology, and Molecular Biology. Their work spans several subfields including Pulmonary and Respiratory Medicine as well as Molecular Medicine.

The scientist's main research topics include:

  • SARS-CoV-2 and COVID-19 Research
  • Respiratory viral infections research
  • COVID-19 Clinical Research Studies
  • Pneumonia and Respiratory Infections
  • Viral gastroenteritis research and epidemiology
  • Antibiotic Resistance in Bacteria
  • Monoclonal and Polyclonal Antibodies Research

Frequent collaborators include Katie Streicher, Yueh-Ming Loo, Seth Seegobin, Alexey Ruzin, and Kim Rosenthal. These co-authors have contributed significantly to the breadth of studies in which Mark T. Esser has participated.

Mark T. Esser has published extensively in several key venues, including:

  • Open Forum Infectious Diseases
  • Nature Communications
  • Science Translational Medicine
  • bioRxiv (Cold Spring Harbor Laboratory)
  • The Lancet Respiratory Medicine

Some of their recent papers are:

  • Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants, 2020, New England Journal of Medicine
  • Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail, 2021, Nature Microbiology
  • Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial, 2022, The Lancet Respiratory Medicine
  • The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans, 2022, Science Translational Medicine
  • SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity, 2021, Cell Reports

Best Publications

  • Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

    Luisa L. Villa;Gonzalo Perez;Susanne K. Kjaer;Jorma Paavonen

  • Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.

    Suzanne M. Garland;Suzanne M. Garland;Mauricio Hernandez-Avila;Cosette M. Wheeler;Gonzalo Perez

  • Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

    Luisa L. Villa;Ronaldo L.R. Costa;Carlos A. Petta;Rosires P. Andrade

  • Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials

    Elmar A Joura;Sepp Leodolter;Mauricio Hernandez-Avila;Cosette M Wheeler

  • High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

    L. L. Villa;R. L. R. Costa;C. A. Petta;R. P. Andrade

  • Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants.

    M. Pamela Griffin;Yuan Yuan;Therese Takas;Joseph B. Domachowske

  • Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18

    Luisa L. Villa;Kevin A. Ault;Anna R. Giuliano;Ronaldo L.R. Costa

  • Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.

    Nubia Muñoz;Ricardo Manalastas;Punee Pitisuttithum;Damrong Tresukosol

  • Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins.

    JL Rossio;MT Esser;K Suryanarayana;DK Schneider

  • Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine

    Sven-Eric Olsson;Luisa L. Villa;Ronaldo L.R. Costa;Carlos A. Petta

  • Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial.

    Keith S. Reisinger;Stan L. Block;Eduardo Lazcano-Ponce;Rudiwilai Samakoses

  • Simultaneous Quantitation of Antibodies to Neutralizing Epitopes on Virus-Like Particles for Human Papillomavirus Types 6, 11, 16, and 18 by a Multiplexed Luminex Assay

    David Opalka;Charles E. Lachman;Stefani A. MacMullen;Kathrin U. Jansen

  • The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in non-human primates and has an extended half-life in humans

    Unknown

  • Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial

    Unknown

  • Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18

    Dennis Dias;Jeff Van Doren;Sonela Schlottmann;Sheri Kelly

  • Memory T cells and vaccines.

    Mark T. Esser;Rocio D. Marchese;Lisa S. Kierstead;Lynda G. Tussey

  • Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail.

    Jinhui Dong;Seth J Zost;Allison J Greaney;Allison J Greaney;Tyler N Starr

  • Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection

    Luisa L. Villa;Gonzalo Perez;Susanne Krüger Kjær;Jorma Paavonen

  • Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains

    Unknown

  • Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old.

    Myron J Levin;Anna-Barbara Moscicki;Lin-Ye Song;Terrence Fenton

  • Safety, Tolerability and Pharmacokinetics of MEDI8897, an Extended Half-life Single-dose Respiratory Syncytial Virus Prefusion F-targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants.

    Joseph B. Domachowske;Anis A. Khan;Mark T. Esser;Kathryn Jensen

  • Differential Incorporation of CD45, CD80 (B7-1), CD86 (B7-2), and Major Histocompatibility Complex Class I and II Molecules into Human Immunodeficiency Virus Type 1 Virions and Microvesicles: Implications for Viral Pathogenesis and Immune Regulation

    Mark T. Esser;David R. Graham;Lori V. Coren;Charles M. Trubey

  • Cyanovirin-N Binds to gp120 To Interfere with CD4-Dependent Human Immunodeficiency Virus Type 1 Virion Binding, Fusion, and Infectivity but Does Not Affect the CD4 Binding Site on gp120 or Soluble CD4-Induced Conformational Changes in gp120

    Mark T. Esser;Toshiyuki Mori;Isabelle Mondor;Quentin J. Sattentau

  • An oligosaccharide-based HIV-1 2G12 mimotope vaccine induces carbohydrate-specific antibodies that fail to neutralize HIV-1 virions

    Joseph G. Joyce;Isaac J. Krauss;Hong C. Song;David W. Opalka

Frequent Co-Authors

Luisa L. Villa
Luisa L. Villa Universidade de São Paulo
Judith Falloon
Judith Falloon Horizon Therapeutics (United States)
Laura A. Koutsky
Laura A. Koutsky University of Washington
Kathrin U. Jansen
Kathrin U. Jansen Pfizer (United States)
Jorma Paavonen
Jorma Paavonen University of Helsinki
Cosette M. Wheeler
Cosette M. Wheeler University of New Mexico
Jesse D. Bloom
Jesse D. Bloom Fred Hutchinson Cancer Research Center
Alfred J. Saah
Alfred J. Saah MSD (United States)
Ligia A. Pinto
Ligia A. Pinto Leidos (United States)
Allan Hildesheim
Allan Hildesheim National Institutes of Health

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Immunology in the USA opens doors to various related healthcare careers, many of which offer flexible online education options. For those interested in nursing with a focus on immunological care, exploring an accelerated FNP program can be a fast track to becoming a Family Nurse Practitioner. This specialization often serves as a foundation to advance into more acute care settings.

Transitioning from an FNP role to acute care requires additional certification, and understanding the pathway to fnp to acute care certification is crucial for career growth. This shift allows practitioners to handle more complex immunology-related cases often seen in hospital environments.

For those starting without a nursing background, enrolling in online ADN programs for non nurses provides an accessible entry point into nursing. These programs prepare students for nursing licenses and set the stage for advanced studies in immunology or related nursing fields.

Financial considerations are also important. Understanding how much does a dnp make can help you gauge the return on investment for pursuing a Doctor of Nursing Practice degree, especially if you aim to take on leadership roles within immunology-focused healthcare settings.

Best Scientists Citing Mark T. Esser

Trending Scientists

Recently Published Articles